Activity of Bacteriophages in Murine Tumor Models Depends on the Route of Phage Administration
Previously we investigated the anticancer activity of bacteriophage preparations in various murine tumor models. We demonstrated the antimetastatic activity of purified and nonpurified bacteriophage preparations injected intraperitoneally (IP). However, in solid tumors we observed antitumor activity of purified bacteriophages, but the lysates (raw preparations obtained by culturing phages with bacteria) stimulated tumor growth. In this article we present a comparison of the antitumor activity of bacteriophages after oral (per os, PO) and IP administration of lysates and purified preparations. Our observations indicate that PO application of a bacteriophage preparation is safer and at least as effective as IP. Stimulation of solid tumors by lysates administered orally was not observed, and bacteriophages applied PO were more effective in inhibiting metastases formation. These observations are of great importance in any consideration of possible therapeutic applications of bacteriophages. The role of the route of bacteriophage administration should be considered in the context of the effectiveness and safety of such therapies.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
Document Type: Research Article
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland, Jan Dlugosz Academy, Waszyngtona 418, 42-200 Czestochowa, Poland
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wroclaw, Poland, Institute of Transplantology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland
Publication date: 2005-04-01
More about this publication?
Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.